Brief: Clover Biopharmaceuticals- Doses 1St Participants In Phase I Trial With Scb-2020S, Potentially Broadly Protective- Chimeric Covid-19 Vaccine Candidate
31/05/2022 14:27
Clover Biopharmaceuticals Ltd 2197.HK :
* CLOVER BIOPHARMACEUTICALS- DOSES 1ST PARTICIPANTS IN PHASE
I
TRIAL WITH SCB-2020S, POTENTIALLY BROADLY PROTECTIVE- CHIMERIC
COVID-19 VACCINE CANDIDATE
Source text for Eikon: ID:
Further company coverage: 2197.HK
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune